subscribeSubscribe
Novartis` Generic Tafinlar (Dabrafenib) Receives Approval in the U.S.

Novartis` Generic Tafinlar (Dabrafenib) Receives Approval in the U.S.
FDA
16 Mar 2023
Share Share
JS InnoPharm Initiates Treatment With JSI-1187, a Selective ERK Inhibitor

JS InnoPharm Initiates Treatment With JSI-1187, a Selective ERK Inhibitor
BUSINESSWIRE
03 Jan 2023
Share Share
Spirita Oncology, LLC Initiates a Ph1 Trial of the Anti-Cancer Agent E6201

Spirita Oncology, LLC Initiates a Ph1 Trial of the Anti-Cancer Agent E6201
BUSINESSWIRE
30 Nov 2022
Share Share
Novartis drug combo shows promise in childhood brain cancer

Novartis drug combo shows promise in childhood brain cancer
L. Burger REUTERS
07 Jun 2022
Share Share
Novartis Presents Data From PhIII Trial Of Spartalizumab With Tafinlar &Mekinist

Novartis Presents Data From PhIII Trial Of Spartalizumab With Tafinlar &Mekinist
PRESS RELEASE
20 Sep 2020
Share Share
Novartis` Tafinlar/Mekinist combo improves survival in new Phase 3 data

Novartis` Tafinlar/Mekinist combo improves survival in new Phase 3 data
PHARMA FILE
17 Sep 2020
Share Share
Novartis Tafinlar+ Mekinis demonstrates survival in stage III melanoma

Novartis Tafinlar+ Mekinis demonstrates survival in stage III melanoma
GLOBENEWSWIRE
16 Sep 2020
Share Share
Novartis’ spartalizumab misses primary goal in melanoma study

Novartis’ spartalizumab misses primary goal in melanoma study
CLINICALTRIALS
24 Aug 2020
Share Share
Novartis` melanoma combo fails in PhIII

Novartis` melanoma combo fails in PhIII
Selina McKee PHARMATIMES
23 Aug 2020
Share Share
Targeted therapy combination effective for patients with cholangiocarcinoma

Targeted therapy combination effective for patients with cholangiocarcinoma
NEWSBREAK
18 Aug 2020
Share Share